Virology of hepatitis C virus infection

Best Practice and Research: Clinical Gastroenterology

Volumn 26, Issue 4, 2012, Pages 381-389

  Chevaliez, Stéphane ^a,b   Pawlotsky, Jean Michel ^a,b  

^a HENRI MONDOR HOSPITAL   (France)

^b INSERM U955   (France)

Author keywords

Boceprevir; HCV genotype determination; HCV lifecycle; HCV RNA quantification; Pegylated IFN ; Real time PCR; Ribavirin; Telaprevir

Indexed keywords

BOCEPREVIR; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR; VIRUS PROTEIN;

ANTIBODY DETECTION; BLOOD SAMPLING; CELL CULTURE; CLINICAL PRACTICE; DIAGNOSTIC PROCEDURE; DRUG TARGETING; ENZYME IMMUNOASSAY; GENOTYPE; HEPATITIS C; HUMAN; LABORATORY TEST; LIFE CYCLE; MOLECULAR BIOLOGY; NONHUMAN; POINT OF CARE TESTING; PROTEIN SYNTHESIS; REVIEW; SEQUENCE ANALYSIS; TREATMENT DURATION; TREATMENT PLANNING; TREATMENT RESPONSE; VIRUS REPLICATION;

EID: 84870427238     PISSN: 15216918     EISSN: 15321916     Source Type: Journal    
DOI: 10.1016/j.bpg.2012.09.006     Document Type: Article

References (47)

1. H. Barth, C. Schafer, M.I. Adah, F. Zhang, R.J. Linhardt, and H. Toyoda Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate J Biol Chem 278 2003 41003 41012
2. H. Barth, E.K. Schnober, F. Zhang, R.J. Linhardt, E. Depla, and B. Boson Viral and cellular determinants of the hepatitis C virus envelope-heparan sulfate interaction J Virol 80 2006 10579 10590
3. V. Agnello, G. Abel, M. Elfahal, G.B. Knight, and Q.X. Zhang Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor Proc Natl Acad Sci U S A 96 1999 12766 12771
4. A. Albecka, S. Belouzard, A.O. de Beeck, V. Descamps, L. Goueslain, and J. Bertrand-Michel Role of low-density lipoprotein receptor in the hepatitis C virus life cycle Hepatology 55 2012 998 1007
5. E.G. Cormier, F. Tsamis, F. Kajumo, R.J. Durso, J.P. Gardner, and T. Dragic CD81 is an entry coreceptor for hepatitis C virus Proc Natl Acad Sci U S A 101 2004 7270 7274
6. P. Pileri, Y. Uematsu, S. Campagnoli, G. Galli, F. Falugi, and R. Petracca Binding of hepatitis C virus to CD81 Science 282 1998 938 941
7. B. Bartosch, A. Vitelli, C. Granier, C. Goujon, J. Dubuisson, and S. Pascale Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor J Biol Chem 278 2003 41624 41630
8. E. Scarselli, H. Ansuini, R. Cerino, R.M. Roccasecca, S. Acali, and G. Filocamo The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus EMBO J 21 2002 5017 5025
9. C. Voisset, N. Callens, E. Blanchard, A. Op De Beeck, J. Dubuisson, and N. Vu-Dac High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I J Biol Chem 280 2005 7793 7799
10. M.J. Evans, T. von Hahn, D.M. Tscherne, A.J. Syder, M. Panis, and B. Wolk Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry Nature 446 2007 801 805
11. A. Ploss, M.J. Evans, V.A. Gaysinskaya, M. Panis, H. You, and Y.P. de Jong Human occludin is a hepatitis C virus entry factor required for infection of mouse cells Nature 457 2009 882 886
12. J. Lupberger, M.B. Zeisel, F. Xiao, C. Thumann, I. Fofana, and L. Zona EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy Nat Med 17 2011 589 595
13. B. Sainz Jr., N. Barretto, D.N. Martin, N. Hiraga, M. Imamura, and S. Hussain Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor Nat Med 18 2012 281 285
14. M. Honda, M.R. Beard, L.H. Ping, and S.M. Lemon A phylogenetically conserved stem-loop structure at the 5′ border of the internal ribosome entry site of hepatitis C virus is required for cap-independent viral translation J Virol 73 1999 1165 1174
15. D. Moradpour, F. Penin, and C.M. Rice Replication of hepatitis C virus Nat Rev Microbiol 5 2007 453 463
16. Y. Gwack, D.W. Kim, J.H. Han, and J. Choe DNA helicase activity of the hepatitis C virus nonstructural protein 3 Eur J Biochem 250 1997 47 54
17. C.L. Tai, W.K. Chi, D.S. Chen, and L.H. Hwang The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3) J Virol 70 1996 8477 8484
18. D. Egger, B. Wolk, R. Gosert, L. Bianchi, H.E. Blum, and D. Moradpour Expression of hepatitis C virus proteins induces distinct membrane alterations including a candidate viral replication complex J Virol 76 2002 5974 5984
19. M. Elazar, P. Liu, C.M. Rice, and J.S. Glenn An N-terminal amphipathic helix in hepatitis C virus (HCV) NS4B mediates membrane association, correct localization of replication complex proteins, and HCV RNA replication J Virol 78 2004 11393 11400
20. S.N. Gretton, A.I. Taylor, and J. McLauchlan Mobility of the hepatitis C virus NS4B protein on the endoplasmic reticulum membrane and membrane-associated foci J Gen Virol 86 2005 1415 1421
21. R. Bartenschlager, M. Frese, and T. Pietschmann Novel insights into hepatitis C virus replication and persistence Adv Virus Res 63 2004 71 180
22. T. Shimoike, S. Mimori, H. Tani, Y. Matsuura, and T. Miyamura Interaction of hepatitis C virus core protein with viral sense RNA and suppression of its translation J Virol 73 1999 9718 9725
23. Y. Tanaka, T. Shimoike, K. Ishii, R. Suzuki, T. Suzuki, and H. Ushijima Selective binding of hepatitis C virus core protein to synthetic oligonucleotides corresponding to the 5′ untranslated region of the viral genome Virology 270 2000 229 236
24. R. Bartenschlager, F. Penin, V. Lohmann, and P. Andre Assembly of infectious hepatitis C virus particles Trends Microbiol 19 2011 95 103
25. M. Bouvier-Alias, K. Patel, H. Dahari, S. Beaucourt, P. Larderie, and L. Blatt Clinical utility of total HCV core antigen quantification: a new indirect marker of HCV replication Hepatology 36 2002 211 218
26. V. Descamps, A. Op de Beeck, C. Plassart, E. Brochot, C. Francois, and F. Helle Strong correlation between liver and serum levels of hepatitis C virus core antigen and RNA in chronically infected patients J Clin Microbiol 50 2012 465 468
27. S. Hosseini-Moghaddam, E. Iran-Pour, C. Rotstein, S. Husain, L. Lilly, and E. Renner Hepatitis C core Ag and its clinical applicability: potential advantages and disadvantages for diagnosis and follow-up? Rev Med Virol 22 2012 156 165
28. Y. Park, J.H. Lee, B.S. Kim, Do Y. Kim, K.H. Han, and H.S. Kim New automated hepatitis C virus (HCV) core antigen assay as an alternative to real-time PCR for HCV RNA quantification J Clin Microbiol 48 2010 2253 2256
29. I. Mederacke, A. Potthoff, D. Meyer-Olson, M. Meier, R. Raupach, and M.P. Manns HCV core antigen testing in HIV- and HBV-coinfected patients, and in HCV-infected patients on hemodialysis J Clin Virol 53 2012 110 115
30. M. Miedouge, K. Saune, N. Kamar, M. Rieu, L. Rostaing, and J. Izopet Analytical evaluation of HCV core antigen and interest for HCV screening in haemodialysis patients J Clin Virol 48 2010 18 21
31. G.A. Moscato, G. Giannelli, B. Grandi, D. Pieri, O. Marsi, and I. Guarducci Quantitative determination of hepatitis C core antigen in therapy monitoring for chronic hepatitis C Intervirology 54 2010 61 65
32. R.S. Ross, S. Viazov, S. Salloum, P. Hilgard, G. Gerken, and M. Roggendorf Analytical performance characteristics and clinical utility of a novel assay for total hepatitis C virus core antigen quantification J Clin Microbiol 48 2010 1161 1168
33. European Association for the Study of the Liver EASL clinical practice guidelines: management of hepatitis C virus infection J Hepatol 55 2011 245 264
34. M.G. Ghany, D.R. Nelson, D.B. Strader, D.L. Thomas, and L.B. Seeff An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the study of liver diseases Hepatology 54 2011 1433 1444
35. M.G. Ghany, D.B. Strader, D.L. Thomas, and L.B. Seeff Diagnosis, management, and treatment of hepatitis C: an update Hepatology 49 2009 1335 1374
36. S. Chevaliez, C. Rodriguez, and J.M. Pawlotsky New virologic tools for management of chronic hepatitis B and C Gastroenterology 142 2012 1303 1313
37. S. Chevaliez, M. Bouvier-Alias, R. Brillet, and J.M. Pawlotsky Hepatitis C virus (HCV) genotype 1 subtype identification in new HCV drug development and future clinical practice PLoS One 4 2009 e8209
38. S. Chevaliez, C. Rodriguez, A. Soulier, A. Ahmed-Belkacem, C. Hézode, and J.M. Pawlotsky Molecular characterization of HCV resistance to telaprevir by means of ultra-deep pyrosequencing: preexisting resistant variants and dynamics of resistant populations J Hepatol 54 Suppl. 1 2011 S30
39. E. Tuaillon, A.M. Mondain, F. Meroueh, L. Ottomani, M.C. Picot, and N. Nagot Dried blood spot for hepatitis C virus serology and molecular testing Hepatology 51 2010 752 758
40. C. Moreno, P. Deltenre, J.M. Pawlotsky, J. Henrion, M. Adler, and P. Mathurin Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis J Hepatol 52 2010 25 31
41. M. Diago, M.L. Shiffman, J.P. Bronowicki, S. Zeuzem, M. Rodriguez-Torres, and S.C. Pappas Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin Hepatology 51 2010 1897 1903
42. T. Berg, M. von Wagner, S. Nasser, C. Sarrazin, T. Heintges, and T. Gerlach Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin Gastroenterology 130 2006 1086 1097
43. M. Buti, Y. Lurie, N.G. Zakharova, N.P. Blokhina, A. Horban, and G. Teuber Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response Hepatology 52 2010 1201 1207
44. J.M. Sanchez-Tapias, M. Diago, P. Escartin, J. Enriquez, M. Romero-Gomez, and R. Barcena Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment Gastroenterology 131 2006 451 460
45. J.M. Pawlotsky Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus Hepatology 53 2011 1742 1751
46. J.C. Sullivan, S. De Meyer, D.J. Bartels, I. Dierynck, E. Zhang, and J. Spanks Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials J Hepatol 54 2011 S4
47. S. Zeuzem, R.J. Barnard, J.A. Howe, R.A. Ogert, R. Ralston, and N. Boparai Boceprevir resistance-associated variants (RAVs) are observed more frequently in HCV (GT1)-infected patients with poor response to peginterferon alfa-2b/ribavirin J Hepatol 54 Suppl. 1 2011 S4